|Values are valid only on day of printing.|
Human epididymis protein 4 (HE4) belongs to the family of whey acidic four-disulfide core proteins. Currently, the biologic function of HE4 is unknown.
HE4 has been shown to be overexpressed in 93% of serous, 100% of endometrioid, and 50% of clear cell ovarian carcinomas. In a study of 233 patients with a pelvic mass, including 67 with epithelial ovarian cancer, HE4 had a higher sensitivity for ovarian cancer detection than cancer antigen 125 (CA 125), 72.9% versus 43.3%, respectively, at a specificity of 95%. Researchers also found HE4 to be elevated in more than half of the ovarian cancer patients who did not have elevated CA 125 levels; therefore, the combination of markers provided slightly improved cancer diagnostic sensitivity for the detection of ovarian cancer.
The main established application of HE4 is in post-therapy monitoring of ovarian cancer patients, who had elevated pretreatment levels. In this setting, it complements CA 125 measurement and facilitates follow-up of patients with little or no CA 125 pretreatment elevations.
Certain histological types of ovarian cancer (mucinous or germ cell tumors) rarely express HE4, therefore the use of HE4 is not recommended for monitoring of patients with these types of ovarian cancer.
An aid in monitoring patients with treated epithelial ovarian cancer for recurrence or progression
Increase in human epididymis protein 4 (HE4) suggests recurrence or disease progression, while a decrease suggests therapeutic response. A change in serum HE4 concentration of > or =20% is considered significant.
Twelve hours before this blood test, do not take multivitamins or dietary supplements containing biotin or vitamin B7 that are commonly found in hair, skin and nail supplements and multivitamins.
Results cannot be interpreted as absolute evidence of the presence or absence of malignant ovarian disease, because mild elevations of human epididymis protein 4 (HE4) might also be present in individuals with benign gynecologic conditions (ovarian cysts, cystadenomas, leiomyomas, myomas, fibromas, and endometriosis), hypertension, congestive heart failure, renal and liver disease.
Serial testing for patient HE4 results should be used in conjunction with other clinical methods for monitoring ovarian cancer.
HE4 should not be used as a screening test for ovarian cancer.
The use of this test in disease states other than ovarian cancer has not been clinically validated.
Serum markers are not specific for malignancy and values may vary by method. Values obtained with different assay methods cannot be used interchangeably. Correlation studies between this method and the previous ELISA method (Test ID FHE4) show good correlation (correlation coefficient =0.92). However the new method will, on average, give 28% higher HE4 concentrations and individual patient results may vary more than would be calculated from the correlation equation.
Ideally, when changing methods, parallel testing using the old and new method will allow establishing the patient's HE4 baseline levels with the new method (rebaseline).
In rare cases, interference due to extremely high titers of antibodies to analyte-specific reagents (human anti-mouse or heterophile antibodies, streptavidin, or ruthenium) can occur. The laboratory should be alerted if the result does not correlate with the clinical presentation.
Females: < or =140 pmol/L
Males: Not applicable
1. Moore RG, Brown AK, Miller MC, et al: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008 Feb;108(2):402-408
2. Ferraro S, Braga F, Lanzoni M, et al: Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol 2013 Apr;66(4):273-281